Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.63 |
| ▸ | HTR2C | P28335 | 6/20 | 0.58 |
| ▸ | HTR2A | P28223 | 5/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253589 | 0.87 | HTR2C (0.55) | HTR7HTR2CHTR2APRMT5PRMT1 | |
| SCHEMBL7253587 | 0.87 | HTR2C (0.55) | HTR7HTR2CHTR2APRMT5PRMT1 | |
| SCHEMBL7253595 | 0.87 | HTR2C (0.55) | HTR7HTR2CHTR2APRMT5PRMT1 | |
| SCHEMBL12474064 | 0.86 | HTR2C (0.77) | HTR7HTR2CHTR2APRMT5 | |
| SCHEMBL7258397 | 0.84 | HTR2C (0.52) | HTR7HTR2CHTR2APRMT5PRMT1 | |
| SCHEMBL7258395 | 0.84 | HTR2C (0.52) | HTR7HTR2CHTR2APRMT5PRMT1 | |
| SCHEMBL26675197 | 0.83 | HTR7 (0.60) | HTR7HTR2CHTR2APRMT5 | |
| SCHEMBL7258385 | 0.82 | HTR2C (0.50) | HTR7HTR2CHTR2APRMT5PRMT1 | |
| SCHEMBL25154150 | 0.81 | HTR2C (0.76) | HTR7HTR2CHTR2APRMT5 | |
| SCHEMBL20618352 | 0.81 | HTR7 (0.51) | HTR7HTR2CHTR2APRMT5PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | HTR7 3434/4885HTR2C 3626/4885HTR2A 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.